Inducing huntingtin inclusion formation in primary neuronal cell culture and in vivo by high-capacity adenoviral vectors expressing truncated and full-length huntingtin with polyglutamine expansion

Journal of Gene Medicine

Volumn 10, Issue 3, 2008, Pages 269-279

  Huang, Bin ^a   Schiefer, Johannes ^b   Sass, Christian ^b   Kosinski, Christoph M ^b   Kochanek, Stefan ^a  

^a UNIVERSITY OF ULM   (Germany)

^b UNIVERSITY HOSPITAL RWTH AACHEN   (Germany)

Author keywords

Adenovirus; Gene transfer; Huntingtin; Huntington's disease; Polyglutamine

Indexed keywords

ADENOVIRUS VECTOR; HUNTINGTIN; POLYGLUTAMINE;

ANIMAL CELL; ARTICLE; CELL COMPARTMENTALIZATION; CELL INCLUSION; CELL ISOLATION; CELLULAR DISTRIBUTION; CONTROLLED STUDY; DISEASE MARKER; EMBRYO; EXPRESSION VECTOR; GENE MUTATION; GENETIC TRANSDUCTION; HUNTINGTON CHOREA; IN VIVO STUDY; MOUSE; NERVE CELL CULTURE; NONHUMAN; PRIORITY JOURNAL; PROTEIN FUNCTION; WILD TYPE;

ADENOVIRIDAE; ANIMALS; CELL CULTURE TECHNIQUES; CORPUS STRIATUM; GENETIC VECTORS; HUNTINGTON DISEASE; INCLUSION BODIES; MICE; MICE, INBRED BALB C; NERVE TISSUE PROTEINS; NEURONS; NUCLEAR PROTEINS; PEPTIDES; TRINUCLEOTIDE REPEAT EXPANSION;

ADENOVIRIDAE; ANIMALIA; MUS; RATTUS;

EID: 40549083020     PISSN: 1099498X     EISSN: 15212254     Source Type: Journal    
DOI: 10.1002/jgm.1150     Document Type: Article

References (43)

1. Bates GP, Harper PS, Jones AS (eds). Huntington's Disease, Oxford University Press: Oxford, UK, 2002.
2. Vonsattel JP, DiFiglia M. Huntington disease. J Neuropathol Exp Neurol 1998; 57: 369-384.
3. DiFiglia M, Sapp E, Chase KO, et al. Aggregation of huntingtin in neuronal intranuclear inclusions and dystrophic neurites in brain. Science 1997; 277: 1990-1993.
4. Sapp E, Schwarz C, Chase K, et al. Huntingtin localization in brains of normal and Huntington's disease patients. Ann Neurol 1997; 42: 604-612.
5. Gutekunst CA, Li SH, Yi H, et al. Nuclear and neuropil aggregates in Huntington's disease: relationship to neuropathology. J Neurosci 1999; 19: 2522-2534.
6. van Roon-Morn WM, Hogg VM, Tippett LJ, et al. Aggregate distribution in frontal and motor cortex in Huntington's disease brain. Neuroreport 2006; 17: 667-670.
7. The Huntington's Disease Collaborative Research Group. A novel gene containing a trinucleotide repeat that is expanded and unstable on Huntington's disease chromosomes. Cell 1993; 72: 971-983.
8. Saudou F, Finkbeiner S, Devys D, et al. Huntingtin acts in the nucleus to induce apoptosis but death does not correlate with the formation of intranuclear inclusions. Cell 1998; 95: 55-66.
9. Kim M, Lee HS, LaForet G, et al. Mutant huntingtin expression in clonal striatal cells: dissociation of inclusion formation and neuronal survival by caspase inhibition. J Neurosci 1999; 19: 964-973.
10. Arrasate M, Mitra S, Schweitzer ES, et al. Inclusion body formation reduces levels of mutant huntingtin and the risk of neuronal death. Nature 2004; 431: 805-810.
11. Martindale D, Hackam A, Wieczorek A, et al. Length of huntingtin and its polyglutarnine tract influences localization and frequency of intracellular aggregates. Nat Genet 1998; 18: 150-154.
12. Chan EY, Luthi-Carter R, Strand A, et al. Increased huntingtin protein length reduces the number of polyglutamine-induced gene expression changes in mouse models of Huntington's disease. Hum Mol Genet 2002; 11: 1939-1951.
13. Yu ZX, Li SH, Evans J, et al. Mutant huntingtin causes context-dependent neurodegeneration in mice with Huntington's disease. J Neurosci 2003; 23: 2193-2202.
14. Graham RK, Deng Y, Slow EJ, et al. Cleavage at the caspase-6 site is required for neuronal. dysfunction and degeneration due to mutant huntingtin. Cell 2006; 125: 1179-1191.
15. Bates GP, Hockly E. Experimental therapeutics in Huntingtons disease: are models useful for therapeutic trials? Curr Opin Neurol 2003; 16: 465-470.
16. Senut MC, Suhr ST, Kaspar B, et al. Intraneuronal aggregate formation and cell death after viral expression of expanded polyglutamine tracts in the adult rat brain. J Neurosci 2000; 20: 219-229.
17. de Almeida LP, Ross CA, Zala D, et al. Lentiviral-mediated delivery of mutant huntingtin in the striatum of rats induces a selective neuropathology modulated by polyglutamine repeat size, huntingtin expression levels, and protein length. J Neurosci 2002; 22: 3473-3483.
18. Regulier E, Trottier Y, Perrin V, et al. Early and reversible neuropathology induced by tetracycline-regulated lentiviral overexpression of mutant huntingtin in rat striatum. Hum Mol Genet 2003; 12: 2827-2836.
19. Tagawa K, Hoshino M, Okuda T, et al. Distinct aggregation and cell death patterns among different types of primary neurons induced by mutant huntingtin protein. J Neurochem 2004; 89: 974-987.
20. Zala D, Benchoua. A, Brouillet E, et al. Progressive and selective striatal degeneration in primary neuronal cultures using lentiviral vector coding for a mutant huntingtin fragment. Neurobiol Dis 2005; 20: 785-798.
21. Dinser R, Kreppel F, Zaucke F, et al. Comparison of long-term transgene expression after non-viral and adenoviral gene transfer into primary articular chondrocytes. Histochem. Cell Biol 2001; 116: 69-77.
22. Parks RJ, Chen L, Anton M, et al. A helper-dependent adenovirus vector system: removal of helper virus by Cre-mediated excision of the viral packaging signal. Proc Natl Acad Sci U S A 1996; 93: 13565-13570.
23. Schiedner G, Mortal N, Parks RJ, et al. Genomic DNA transfer with a high-capacity adenovirus; vector results in improved in vivo gene expression and decreased toxicity. Nat Genet 1998; 18: 180-183.
24. Kreppel F, Biermann V, Kochanek S, et al. A DNA-based method to assay total and infectious particle contents and helper virus contamination in high-capacity adenoviral vector preparations. Hum Gene Ther 2002; 13: 1151-1156.
25. Huang B, Kochanek S. Adenovirus-mediated silencing of huntingtin expression by shRNA. Hum Gene Ther 2005; 16: 618-626.
26. Glover CP, Bienemann AS, Heywood DJ, et al. Adenoviral-mediated, high-level, cell-specific transgene expression: a SYN1-WPRE cassette mediates increased transgene expression with no loss of neuron specificity. Mol Ther 2002; 5: 509-516.
27. Kügler S, Kilic E, Bahr M. Human synapsin 1 gene promoter confers highly neuron-specific long-term transgene expression from an adenoviral vector in the adult rat brain depending on the transduced area. Gene Ther 2003; 10: 337-347.
28. Li SH, Li XJ. Huntingtin and its role in neuronal degeneration Neuroscientist 2004; 10: 467-475.
29. Landles C, Bates GP. Huntingtin and the molecular pathogenesis of Huntington' s disease. Fourth in molecular medicine review series. EMBO Rep 2004; 5: 958-963.
30. Rubinsztein DC. Lessons from animal models of Huntington's disease. Trends Genet 2002; 18: 202-209.
31. MacDonald ME, Gines S, Gusella JF, et al. Huntington's disease. Neuromolecular Med 2003; 4: 7-20.
32. Valera AG, Diaz-Hernandez M, Hernandez F, et al. The ubiquitin-proteasome system in Huntington's disease. Neuroscientist 2005; 11: 583-594.
33. Davies SW, Turmaine M, Cozens BA, et al. Formation of neuronal intranuclear inclusions underlies the neurological dysfunction in mice transgenic for the HD mutation. Cell 1997; 90: 537-548.
34. Scherzinger E, Lurz R, Turmaine M, et al. Huntingtin-encoded polyglutamine expansions form amyloid-like protein aggregates in vitro and in vivo. Cell 1997; 90: 549-558.
35. Waelter S, Boeddrich A, Lutz R, et al. Accumulation of mutant huntingtin fragments in aggresome-like inclusion bodies as a result of insufficient protein degradation. Mol Biol Cell 2001; 12: 1393-1407.
36. Martin-Aparicio E, Yamamoto A, Hernandez F, et al. Proteasomal-dependent aggregate reversal and absence of cell death in a conditional mouse model of Huntington's disease. J Neurosci 2001; 21: 8772-8781.
37. Yamamoto A, Lucas JJ, Hen R. Reversal of neuropathology and motor dysfunction in a conditional model of Huntington's disease. Cell 2000; 101: 57-66.
38. Bates GP. Huntingin aggregation and toxicity in Huntington disease. Lancet 2003; 361: 1642-1644.
39. Steffan JS, Thompson LM. Targeting aggregation in the development of therapeutics for the treatment of Huntington's disease and other polyglutamine repeat diseases. Expert Opin Ther Targets 2003; 7: 201-213.
40. Mangiarini L, Sathasivam k, Seller M, et al. Exon 1 of the HD gene with an expanded CAG repeat is sufficient to cause a progressive neurological phenotype in transgenic mice. Cell 1996; 87: 493-506.
41. Hackam AS, Singaraja R, Wellington CL, et al. The influence of huntingtin protein size on nuclear localization and cellular toxicity. J Cell Biol 1998; 141: 1097-1105.
42. Lunkes A, Mandel JL. A cellular model that recapitulates major pathogenic steps of Huntington's disease. Hum Mol Genet 1998; 7: 1355-1361.
43. Zala D, Benchoua A, Brouillet E, et al. Progressive and selective striatal degeneration in primary neuronal cultures using lentiviral vector coding for a mutant huntingtin fragment. Neurobiol Dis 2005; 20: 785-798.